Molecular Characterization of Putative Chordoma Cell Lines

  • Silke Brüderlein
    Institute of Pathology, Ulm University, D-89081 Ulm, Germany
  • Joshua B. Sommer
    Executive Director, Chordoma Foundation, Durham, NC 27702, USA
  • Paul S. Meltzer
    Genetics Branch, National Cancer Institute, Bethesda, MD 20892, USA
  • Sufeng Li
    Department of Medicine, Duke University, Durham, NC 27710, USA
  • Takuya Osada
    Department of Surgery, Duke University, Durham, NC 27710, USA
  • David Ng
    Genetics Branch, National Cancer Institute, Bethesda, MD 20892, USA
  • Peter Möller
    Institute of Pathology, Ulm University, D-89081 Ulm, Germany
  • David A. Alcorta
    Department of Medicine, Duke University, Durham, NC 27710, USA
  • Michael J. Kelley
    Department of Medicine, Duke University, Durham, NC 27710, USA

Description

<jats:p>Immortal tumor cell lines are an important model system for cancer research, however, misidentification and cross-contamination of cell lines are a common problem. Seven chordoma cell lines are reported in the literature, but none has been characterized in detail. We analyzed gene expression patterns and genomic copy number variations in five putative chordoma cell lines (U-CH1, CCL3, CCL4, GB60, and CM319). We also created a new chordoma cell line, U-CH2, and provided genotypes for cell lines for identity confirmation. Our analyses revealed that CCL3, CCL4, and GB60 are not chordoma cell lines, and that CM319 is a cancer cell line possibly derived from chordoma, but lacking expression of key chordoma biomarkers. U-CH1 and U-CH2 both have gene expression profiles, copy number aberrations, and morphology consistent with chordoma tumors. These cell lines also harbor genetic changes, such as loss of p16, MTAP, or PTEN, that make them potentially useful models for studying mechanisms of chordoma pathogenesis and for evaluating targeted therapies.</jats:p>

Journal

  • Sarcoma

    Sarcoma 2010 1-14, 2010

    Wiley

Citations (1)*help

See more

Report a problem

Back to top